Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures

Demers, Virginie; Melo, Magda; Jackevicius, Cynthia; Cox, Jafna; Kalavrouziotis, Dimitri; Rinfret, St├ęphane; Humphries, Karin H.; Johansen, Helen; Tu, Jack V.; Pilote, Louise
February 2008
CMAJ: Canadian Medical Association Journal;2/12/2008, Vol. 178 Issue 4, p405
Academic Journal
Background: Reimbursement for outpatient prescription drugs is not mandated by the Canada Health Act or any other federal legislation. Provincial governments independently establish reimbursement plans. We sought to describe variations in publicly funded provincial drug plans across Canada and to examine the impact of this variation on patients' annual expenditures. Methods: We collected information, accurate to December 2006, about publicly funded prescription drug plans from all 10 Canadian provinces. Using clinical scenarios, we calculated the impact of provincial cost-sharing strategies on individual annual drug expenditures for 3 categories of patients with different levels of income and 2 levels of annual prescription burden ($260 and $1000). Results: We found that eligibility criteria and cost-sharing details of the publicly funded prescription drug plans differed markedly across Canada, as did the personal financial burden due to prescription drug costs. Seniors pay 35% or less of their prescription costs in 2 provinces, but elsewhere they may pay as much as 100%. With few exceptions, nonseniors pay more than 35% of their prescription costs in every province. Most social assistance recipients pay 35% or less of their prescription costs in 5 provinces and pay no costs in the other 5. In an example of a patient with congestive heart failure, his out-of-pocket costs for a prescription burden of $1283 varied between $74 and $1332 across the provinces. Interpretation: Considerable interprovincial variation in publicly funded prescription drug plans results in substantial variation in annual expenditures by Canadians with identical prescription burdens. A revised pharmaceutical strategy might reduce these major inequities.


Related Articles

  • Is legislation required for pharmacists refusing to dispense?  // PharmacoEconomics & Outcomes News;5/6/2006, Issue 502, p2 

    The article discusses research being done on the requirement for legislation when pharmacists refuse to dispense prescriptions. It references a study by K. A. Bramstedt published in the April 15, 2006 issue of "Lancet." It mentions the policy of the American Pharmacists Association concerning...

  • The British National Formulary and other medicine indexes. Dimond, Bridgit // British Journal of Nursing;5/22/2003, Vol. 12 Issue 10, p620 

    Focuses on British legislation governing national formulary and other medicine indexes. Features of the country's nurse prescribers' formulary; Functions of hospitals and community pharmacists under the law.

  • Dear Doctor (Guest Voice). Johnson, Peter W. // Moderate Voice;9/18/2013, p1 

    A personal narrative is presented in which the author explores his experiences of going through the agony of getting a temporary prescription for a heart pill due to requirements of law.

  • Drug and Formulary Trends.  // Formulary;Jul2004, Vol. 39 Issue 7, p366 

    Presents pie graphs showing drug and formulary trends in the United States, as of July 2004. Top therapeutic categories contributing to 2003 drug spending; Projected drug spending by therapeutic category for the years 2004-2006. INSET: Drug and formulary factoids.

  • 'Duty to warn' interpreted in Arkansas, Indiana. Brushwood, David B. // Pharmacy Today;Apr2011, Vol. 17 Issue 4, p20 

    The article presents the author's views on pharmaceutical laws regarding the pharmacist's duty to warn patients of the risks of prescribed drug. He cites separate lawsuits in Arkansas and Indiana wherein one case involved the death of a patient due to multiple drug prescriptions and another case...

  • Pharmacy Compounding; Customizing Prescription Drugs. Nordenberg, Tamar // FDA Consumer;Jul/Aug2000, Vol. 34 Issue 4, p11 

    Reports that the medical use of unapproved drugs may become legally acceptable under a United States pharmacy compounding law that allows pharmacists and doctors to tailor drugs for specific patients. Explanation of compounding; Risk factors of compounded drugs; Reasons why a doctor would...

  • MIXING DRUGS IN SYRINGE DRIVERS IS BREAKING THE LAW. Pountney, David // Cancer Nursing Practice;Sep2008, Vol. 7 Issue 7, p12 

    The article provides information on mixing drugs in syringe drivers. It is stated that mixing drugs in a syringe driver has legal implications and is breaking the law because such action can give way for the creation of new and unlicensed drug not covered by present legal framework. The article...

  • Green Light for Prior Authorization. Wechsler, Jill // Pharmaceutical Executive;May2004, Vol. 24 Issue 5, p20 

    Reports that states in the U.S. may establish formularies and require physicians to seek prior approval to prescribe off-formulary drugs for low-income patients, according to a Court of Appeals ruling for the District of Columbia. Ruling against PhRMA, which had challenged a Michigan program to...

  • New Hurdles Ahead?  // Pharmaceutical Technology Europe;Feb2004, Vol. 16 Issue 2, p14 

    Focuses on the processes by which drugs receive marketing authorization in the pharmaceutical industry. New drugs to be allowed into the market only when they demonstrate added therapeutic values; Requirement of cheapest drugs in countries with little domestic innovative drug industry; Need for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics